Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Profiling normal DNA provides opportunity to identify inherited mutations

As the practice of genetically profiling patient tumors for clinical treatment decision making becomes more commonplace, a recent study from The University of Texas MD Anderson Cancer Center suggests that profiling normal DNA also provides an important opportunity to identify inherited mutations that could be critical for patients and their families.

15 May 2015

Patients with operable early-stage NSCLC could achieve better overall survival rates with SABR

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care -- invasive surgery -- according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.

15 May 2015

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Argos is developing AGS-003, which is a fully personalized immunotherapy designed to induce a durable memory T-cell response specific to each patient’s cancer...

14 May 2015

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy.

14 May 2015

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center.

14 May 2015

CNIO researchers identify new strategy to combat cancer

Scientists from the Spanish National Cancer Research Centre have discovered a new strategy to fight cancer, which is very different from those described to date. Their work shows for the first time that telomeres -- the structures protecting the ends of the chromosomes -- may represent an effective anti-cancer target: by blocking the TRF1 gene, which is essential for the telomeres, they have shown dramatic improvements in mice with lung cancer.

14 May 2015

Loyola study examines survival outcomes in patients with mesenchymal chondrosarcoma

Among the deadliest cancers is a rare malignancy called mesenchymal chondrosarcoma, which begins in cartilage around bones and typically strikes young adults.

13 May 2015

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.

13 May 2015

Researchers develop new tool to identify common genetic anomalies in cancer

Researchers from the University of Michigan Comprehensive Cancer Center and Thermo Fisher Scientific have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples.

13 May 2015

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1.

13 May 2015

Managing cancer at work: Johns Hopkins launches new service for all employees

Johns Hopkins Medicine has created and launched Managing Cancer at Work, a new and novel health benefit program offered free of charge for its more than 42,000 combined full-time equivalent employees.

12 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

Obese people at greater risk of developing cancer

Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this coming Saturday (16 May), metabolic expert Alexandra Kautzky-Willer, Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital, draws attention to the fact that, even in Austria, more and more people are suffering from obesity.

12 May 2015

Research finds link between oestrogen levels and male breast cancer

Men with naturally high levels of the female hormone oestrogen may have a greater risk of developing breast cancer, according to research by an international collaboration including Cancer Research UK published today in the Journal of Clinical Oncology.

12 May 2015

DataMotion continues to experience rapid growth in healthcare industry

DataMotion today announced the company continues to experience rapid growth as a leading health information service provider (HISP) of Direct Secure Messaging for electronic health records (EHR) and HIPAA compliant email encryption. A growing number of EHR system vendors, health information exchanges (HIE) and healthcare providers are selecting both DataMotion Direct and DataMotion SecureMail for their interoperability, scalability and rapid deployment capabilities.

12 May 2015

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome Pharma Corp. today announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD and ESMOCARD LYO (esmolol hydrochloride) in Italy, France, Spain and Belgium.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Oncology News and Research

Further Reading

Profiling normal DNA provides opportunity to identify inherited mutations

Patients with operable early-stage NSCLC could achieve better overall survival rates with SABR

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

MD Anderson researchers find significant clinical variations among liver cancer patients

CNIO researchers identify new strategy to combat cancer

Loyola study examines survival outcomes in patients with mesenchymal chondrosarcoma

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Soligenix, Emergent BioSolutions sign development agreement

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Researchers develop new tool to identify common genetic anomalies in cancer

Research paves way for development of individualized immunotherapy for treating cancer

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Managing cancer at work: Johns Hopkins launches new service for all employees

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

Obese people at greater risk of developing cancer

Research finds link between oestrogen levels and male breast cancer

DataMotion continues to experience rapid growth in healthcare industry

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News